+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sunitinib Malate Market - Global Forecast 2026-2032- Product Image
Sunitinib Malate Market - Global Forecast 2026-2032- Product Image
Sale

Sunitinib Malate Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6084048
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Sunitinib Malate Market is projected to reach USD 166.95 Million in 2026. It is expected to continue growing at a CAGR of 11.69%, reaching USD 322.01 Million by 2032.

Sunitinib Malate: Clinical Role and Market Context

Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor used in selected oncology indications. Its established pharmacology includes inhibition of signaling pathways involving vascular endothelial growth factor receptors, platelet-derived growth factor receptors, KIT, and related kinases. Clinical use is shaped by indication-specific evidence, regulatory labeling, treatment guidelines, patient eligibility, and the availability of alternative targeted and immuno-oncology options.

Treatment Pathways Are Shifting Toward Biomarker-Guided Care

The therapeutic landscape is moving toward more precisely sequenced regimens, molecular characterization, and combination strategies. For sunitinib malate, this shift increases the importance of selecting patients according to tumor type, prior therapy, comorbidities, and treatment goals. Oral administration remains operationally convenient, but sustained use requires structured monitoring for hypertension, fatigue, gastrointestinal effects, dermatologic reactions, hematologic abnormalities, thyroid dysfunction, and cardiac risk.

Artificial Intelligence Strengthens Evidence Generation and Treatment Support

Artificial intelligence can support oncology research by improving clinical-trial matching, extracting structured evidence from medical records, identifying safety signals, and assisting radiologic or pathologic interpretation. Its practical value depends on representative training data, transparent validation, human oversight, and compliance with privacy and medical-device requirements. AI should complement, rather than replace, clinician judgment when assessing response, toxicity, drug interactions, and treatment continuation.

Regional Insights: Access Depends on Regulation, Reimbursement, and Monitoring Capacity

North America generally combines established oncology infrastructure with stringent regulatory and payer requirements. Europe emphasizes health-technology assessment, guideline alignment, and nationally variable reimbursement. Asia-Pacific includes highly diverse regulatory systems, manufacturing capabilities, and access conditions, with Japan, China, South Korea, India, and Australia operating within distinct clinical and policy environments. Latin America commonly faces uneven access, procurement constraints, and differences in specialist capacity. Middle East access varies with national health-system resources and centralized purchasing, while Africa is shaped by affordability, diagnostic capacity, specialist availability, and supply continuity.

Group Insights: Trade Blocs Shape Evidence, Procurement, and Access

ASEAN markets reflect varied regulatory maturity, reimbursement structures, and oncology capacity, making localized access strategies important. BRICS members span different disease burdens, domestic production capabilities, and public-procurement models. The European Union is influenced by coordinated regulatory science alongside country-level pricing and reimbursement decisions. G7 countries generally have advanced oncology services but apply differing evidence, safety, and payer frameworks. GCC systems often rely on centralized procurement and specialist institutions, while NATO members include diverse health systems whose medicine-access policies are not uniform despite shared security cooperation.

Country Insights: Diverse Regulatory and Clinical Environments

Australia and Canada emphasize evidence review and public reimbursement assessment. Brazil and Mexico operate through mixed public-private systems with regional access differences. China, India, Russia, and South Korea have distinct regulatory, procurement, and domestic-manufacturing priorities. Japan applies detailed post-marketing and clinical-use requirements. France, Germany, Italy, Spain, and the United Kingdom combine established oncology networks with country-specific reimbursement, guideline, and health-technology-assessment processes. In the United States, prescribing is governed by federal labeling and payer policies, with access also influenced by specialty care and patient-support pathways.

Leadership Priorities for Safe and Sustainable Use

Industry leaders should prioritize evidence aligned with current treatment pathways, clear patient-selection criteria, and robust comparative safety information. Strengthening pharmacovigilance, adherence support, dose-management education, and interaction screening can improve real-world care. Regional teams should map regulatory and reimbursement requirements separately rather than assuming bloc-wide uniformity. Partnerships with health systems can support diagnostic readiness, clinician education, responsible data use, and continuity of supply without compromising independent clinical decision-making.

Methodology: Evidence Synthesis Across Clinical and Health-System Dimensions

This executive summary uses a structured qualitative review framework centered on the pharmacology, established oncology use, safety considerations, treatment-pathway changes, digital-health applications, and access conditions associated with sunitinib malate. Interpretation is organized across the requested regions, country groups, and countries, while avoiding unsupported market estimates. A rigorous full study would triangulate regulatory labeling, peer-reviewed clinical evidence, treatment guidelines, pharmacovigilance sources, health-technology assessments, reimbursement decisions, and validated healthcare-system data.

Conclusion: Evidence-Led Positioning Remains Essential

Sunitinib malate remains relevant where its labeled indications, clinical evidence, and patient-specific risk-benefit profile support use. Its role is increasingly defined by treatment sequencing, competing targeted and immune-based approaches, monitoring requirements, and health-system access. Leaders can improve outcomes by combining indication-specific evidence, disciplined safety management, responsible digital tools, and locally informed regulatory and reimbursement strategies.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Sunitinib Malate Market, by Indication
7.1. Introduction
7.2. Gastrointestinal Stromal Tumor
7.2.1. Kit Mutant
7.2.2. Pdgra Mutant
7.2.3. Wild Type
7.3. Pancreatic Neuroendocrine Tumor
7.3.1. Functional
7.3.2. Non Functional
7.4. Renal Cell Carcinoma
7.4.1. Clear Cell Carcinoma
7.4.2. Non-Clear Cell Carcinoma
8. Sunitinib Malate Market, by Line Of Treatment
8.1. Introduction
8.2. First Line
8.3. Second Line
8.4. Third Line
9. Sunitinib Malate Market, by End User
9.1. Introduction
9.2. Hospital
9.3. Specialty Clinic
10. Sunitinib Malate Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Sunitinib Malate Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Sunitinib Malate Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Sunitinib Malate Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Active Biotech AB
15.2. Astellas Pharma Inc
15.3. Aurobindo Pharma Ltd
15.4. Beijing Lunarsun Pharmaceutical Co Ltd
15.5. Brawn Laboratories Ltd
15.6. Bristol Myers Squibb Company
15.7. Changzhou Highassay Chemical Co Ltd
15.8. CSPC Pharmaceutical Group Ltd
15.9. Dendreon Pharmaceuticals LLC
15.10. Dr Reddys Laboratories Ltd
15.11. Ferring Pharmaceuticals Inc
15.12. Gonane Pharma
15.13. Hansoh Pharmaceutical Group Company Ltd
15.14. Hikma Pharmaceuticals PLC
15.15. Hunan Ouya Biological Co Ltd
15.16. J K Scientific LLC
15.17. Jeil Pharmaceutical Co Ltd
15.18. Medichem SA
15.19. Mylan NV
15.20. Nanjing First Pharmaceutical Co Ltd
15.21. Natco Pharma Ltd
15.22. Pfizer Inc
15.23. Qilu Pharmaceutical Co Ltd
15.24. Reliance Life Sciences Pvt Ltd
15.25. Shilpa Medicare Ltd
15.26. Sichuan Xieli Pharmaceutical Co Ltd
15.27. Sun Pharmaceutical Industries Ltd
15.28. Target Molecule Corp
15.29. Teva Pharmaceutical Industries Ltd
15.30. Topcare Pharmaceutical Co Ltd
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Sunitinib Malate Market, Years Considered for the Study
FIGURE 2. Global Sunitinib Malate Market, Research Design
FIGURE 3. Global Sunitinib Malate Market, Research Framework
FIGURE 4. Global Sunitinib Malate Market, Data Triangulation
FIGURE 5. Global Sunitinib Malate Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Sunitinib Malate Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Sunitinib Malate Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Sunitinib Malate Market Size, by Line Of Treatment, 2025 vs 2032 (%)
FIGURE 9. Global Sunitinib Malate Market Size, by Line Of Treatment, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Sunitinib Malate Market Size, by End User, 2025 vs 2032 (%)
FIGURE 11. Global Sunitinib Malate Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Sunitinib Malate Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Sunitinib Malate Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Sunitinib Malate Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Sunitinib Malate Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Sunitinib Malate Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Sunitinib Malate Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Sunitinib Malate Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Sunitinib Malate Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Sunitinib Malate Market Segmentation & Coverage
TABLE 2. Global Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 3. Global Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Gastrointestinal Stromal Tumor Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Gastrointestinal Stromal Tumor Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Gastrointestinal Stromal Tumor Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Kit Mutant Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Kit Mutant Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Kit Mutant Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Pdgra Mutant Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Pdgra Mutant Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Pdgra Mutant Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Wild Type Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Wild Type Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Wild Type Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Pancreatic Neuroendocrine Tumor Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Pancreatic Neuroendocrine Tumor Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Pancreatic Neuroendocrine Tumor Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Functional Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Functional Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Functional Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Non Functional Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Non Functional Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Non Functional Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Renal Cell Carcinoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Renal Cell Carcinoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Renal Cell Carcinoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Clear Cell Carcinoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Clear Cell Carcinoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Clear Cell Carcinoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Non-Clear Cell Carcinoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Non-Clear Cell Carcinoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Non-Clear Cell Carcinoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 35. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Third Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Third Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Third Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 45. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Specialty Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Specialty Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Specialty Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 52. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Sunitinib Malate Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Sunitinib Malate Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 67. North America Sunitinib Malate Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. North America Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 69. North America Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 70. North America Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 71. North America Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 72. North America Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 73. North America Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 74. North America Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 75. Latin America Sunitinib Malate Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Latin America Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 77. Latin America Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 78. Latin America Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 79. Latin America Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 80. Latin America Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 81. Latin America Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 82. Latin America Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 83. Europe Sunitinib Malate Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Europe Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 85. Europe Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 86. Europe Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 87. Europe Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 88. Europe Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 89. Europe Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. Europe Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 91. Middle East Sunitinib Malate Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Middle East Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 93. Middle East Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 94. Middle East Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 95. Middle East Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 96. Middle East Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 97. Middle East Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. Middle East Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 99. Africa Sunitinib Malate Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Africa Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 101. Africa Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 102. Africa Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 103. Africa Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 104. Africa Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 105. Africa Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 106. Africa Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 107. Global Sunitinib Malate Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. ASEAN Sunitinib Malate Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. ASEAN Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 110. ASEAN Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 111. ASEAN Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 112. ASEAN Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 113. ASEAN Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 114. ASEAN Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 115. ASEAN Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 116. GCC Sunitinib Malate Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. GCC Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 118. GCC Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 119. GCC Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 120. GCC Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 121. GCC Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 122. GCC Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 123. GCC Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. European Union Sunitinib Malate Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. European Union Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 126. European Union Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 127. European Union Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 128. European Union Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 129. European Union Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 130. European Union Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 131. European Union Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. BRICS Sunitinib Malate Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. BRICS Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 134. BRICS Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 135. BRICS Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 136. BRICS Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 137. BRICS Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 138. BRICS Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 139. BRICS Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 140. G7 Sunitinib Malate Market Size, by Group, 2017-2032 (USD Million)
TABLE 141. G7 Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 142. G7 Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 143. G7 Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 144. G7 Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 145. G7 Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 146. G7 Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 147. G7 Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 148. NATO Sunitinib Malate Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. NATO Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 150. NATO Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 151. NATO Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 152. NATO Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 153. NATO Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 154. NATO Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 155. NATO Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 156. Global Sunitinib Malate Market Size, by Country, 2017-2032 (USD Million)
TABLE 157. United States Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 158. United States Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 159. United States Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 160. United States Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 161. United States Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 162. United States Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 163. United States Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 164. United States Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 165. Canada Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 166. Canada Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 167. Canada Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 168. Canada Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 169. Canada Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 170. Canada Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 171. Canada Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. Canada Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 173. Mexico Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 174. Mexico Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 175. Mexico Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 176. Mexico Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 177. Mexico Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 178. Mexico Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 179. Mexico Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. Mexico Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. Brazil Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 182. Brazil Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 183. Brazil Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 184. Brazil Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 185. Brazil Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 186. Brazil Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 187. Brazil Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 188. Brazil Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 189. United Kingdom Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 190. United Kingdom Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 191. United Kingdom Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 192. United Kingdom Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 193. United Kingdom Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 194. United Kingdom Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 195. United Kingdom Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. United Kingdom Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 197. Germany Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 198. Germany Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 199. Germany Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 200. Germany Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 201. Germany Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 202. Germany Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 203. Germany Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 204. Germany Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. France Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 206. France Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 207. France Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 208. France Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 209. France Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 210. France Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 211. France Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 212. France Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 213. Russia Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 214. Russia Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 215. Russia Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 216. Russia Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 217. Russia Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 218. Russia Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 219. Russia Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. Russia Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 221. Italy Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 222. Italy Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 223. Italy Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 224. Italy Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 225. Italy Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 226. Italy Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 227. Italy Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 228. Italy Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 229. Spain Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 230. Spain Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 231. Spain Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 232. Spain Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 233. Spain Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 234. Spain Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 235. Spain Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. Spain Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 237. China Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 238. China Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 239. China Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 240. China Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 241. China Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 242. China Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 243. China Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. China Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 245. India Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 246. India Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 247. India Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 248. India Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 249. India Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 250. India Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 251. India Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 252. India Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 253. Japan Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 254. Japan Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 255. Japan Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 256. Japan Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 257. Japan Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 258. Japan Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 259. Japan Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 260. Japan Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 261. Australia Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 262. Australia Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 263. Australia Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 264. Australia Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 265. Australia Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 266. Australia Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 267. Australia Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 268. Australia Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 269. South Korea Sunitinib Malate Market Size, 2017-2032 (USD Million)
TABLE 270. South Korea Sunitinib Malate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 271. South Korea Sunitinib Malate Market Size, by Gastrointestinal Stromal Tumor, 2017-2032 (USD Million)
TABLE 272. South Korea Sunitinib Malate Market Size, by Pancreatic Neuroendocrine Tumor, 2017-2032 (USD Million)
TABLE 273. South Korea Sunitinib Malate Market Size, by Renal Cell Carcinoma, 2017-2032 (USD Million)
TABLE 274. South Korea Sunitinib Malate Market Size, by Line Of Treatment, 2017-2032 (USD Million)
TABLE 275. South Korea Sunitinib Malate Market Size, by End User, 2017-2032 (USD Million)
TABLE 276. South Korea Sunitinib Malate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 277. Global Sunitinib Malate Market Share, by Key Player, 2025
TABLE 278. Global Sunitinib Malate Market, Key Experts

Companies Mentioned

  • Active Biotech AB
  • Astellas Pharma Inc
  • Aurobindo Pharma Ltd
  • Beijing Lunarsun Pharmaceutical Co Ltd
  • Brawn Laboratories Ltd
  • Bristol Myers Squibb Company
  • Changzhou Highassay Chemical Co Ltd
  • CSPC Pharmaceutical Group Ltd
  • Dendreon Pharmaceuticals LLC
  • Dr Reddys Laboratories Ltd
  • Ferring Pharmaceuticals Inc
  • Gonane Pharma
  • Hansoh Pharmaceutical Group Company Ltd
  • Hikma Pharmaceuticals PLC
  • Hunan Ouya Biological Co Ltd
  • J K Scientific LLC
  • Jeil Pharmaceutical Co Ltd
  • Medichem SA
  • Mylan NV
  • Nanjing First Pharmaceutical Co Ltd
  • Natco Pharma Ltd
  • Pfizer Inc
  • Qilu Pharmaceutical Co Ltd
  • Reliance Life Sciences Pvt Ltd
  • Shilpa Medicare Ltd
  • Sichuan Xieli Pharmaceutical Co Ltd
  • Sun Pharmaceutical Industries Ltd
  • Target Molecule Corp
  • Teva Pharmaceutical Industries Ltd
  • Topcare Pharmaceutical Co Ltd

Related Topics

Related Reports

Sunitinib Malate - Global Strategic Business Report - Product Image

Sunitinib Malate - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Sunitinib Malate (CAS 341031-54-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Sunitinib Malate (CAS 341031-54-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Sunitinib Generics Market - Global Forecast 2026-2032 - Product Image

Sunitinib Generics Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Sunitinib (CAS 557795-19-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Sunitinib (CAS 557795-19-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Follicular Thyroid Cancer Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Follicular Thyroid Cancer Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Sunitinib Malate Market

Sunitinib malate, marketed under the brand name Sutent among others, falls within the category of targeted oncology drugs, specifically acting as a multi-targeted receptor tyrosine kinase (RTK) inhibitor. Its market presence is dictated by its efficacy in treating various types of cancer, including renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (PNETs). Sunitinib malate operates by blocking multiple molecular targets implicated in the growth, proliferation, and spread of cancer cells. Due to its targeted approach, it represents an alternative to conventional chemotherapy, offering a different side effect profile and method of action. Its utility in the field of oncology continues to be explored with ongoing research assessing its potential application in other malignancies. Several pharmaceutical and biotechnology companies have a stake in the market for sunitinib malate. Pfizer Inc. is the most prominent as the originator and manufacturer of Sutent, the landmark brand of sunitinib. Other companies may be involved in the distribution or production of generic forms of the drug. These include but are not limited to Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V. This market is subject to the stringent regulations and patent laws related to novel oncology therapies, which influence the competitive landscape as well as the availability of generic versions. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.